Published on : Jun 27, 2018
Albany, New York, June 27, 2018: Increased instances of vision loss in adults owing to macular degeneration has encouraged bio-pharmaceutical entities and research institutes to engage in clinical trials that can augment age related macular degeneration therapeutics. To evaluate the implications of recent developments on age related macular degeneration drug development, Market Research Hub (MRH) has entailed a new healthcare study titled, ‘Age Related Macular Degeneration - Pipeline Review, H1 2018’ to its repository.
APL-2 Drug Shows Positive Outcome in Age Related Macular Degeneration Drug Development
Pharmaceutical companies, universities, and research institutes are akin on achieving significant breakthrough in drug development for age related macular degeneration. Several drug development endeavors are at various phases of clinical research to aptly address medical crisis of end-users across regions.
According to a recent report, leading ophthalmological company, Novartis has announced favorable data supporting the efficacy of brolucizumab in age related macular degeneration targeted therapeutics development. This new development was made post-secondary study of Phase III HAWK and HARRIER clinical trials. Brolucizumab, a single-chain antibody fragment (scFv) is integral in drug development, owing to its superior drug delivery characteristics.
Additionally, famed clinical-stage biopharmaceutical company, Apellis Pharmaceuticals, has announced results pertaining to phase-II trial of C3 inhibiting drug, APL-2 for treating geographic atrophy (GA) manifested in age related macular degeneration. According to recent developments in the trial, the company ascertained potency of APL-2 in diminishing progression of GA when injected once in a month in age related macular degeneration patients. Significant reduction was reported upon regular administration of the drug during the tenure of clinical trial. Positive phase II trial results has encouraged the company to carry on next phase trials.
Comprehensive research findings collated in the report presents an overview of various segments prevailing in age related macular degeneration drug development market. Elaborate research findings compiled in the report brief readers about two core segments prevalent in age related macular degeneration drug development market which include, therapeutics development and therapeutics assessment. Based on therapeutics development, age related macular degeneration drug development market is split in terms of drug developed by companies and drug developed by universities. Based on therapeutics assessment, age related macular degeneration drug development market is sectioned as mechanism of action, route of administration, and molecule type. Based on the information collated in the report, readers can gauge the impact of segments in accentuating growth in age related macular degeneration drug development pipeline. Additionally, on the basis of unbiased data compiled in the report, readers can identify effective strategies employed by leading market players in attaining substantial advancement in age related macular degeneration drug development pipeline.
Competition Matrix: Age Related Macular Degeneration Drug Development
Crucial data entailed in the report offers readers with veritable insights about various marketing strategies devised by leading companies in accelerating drug development for age related macular degeneration. Some of the leading players identified in age related macular degeneration drug development market include, Apellis Pharmaceuticals, Allergan Plc, Benitec Biopharma Ltd, Catalyst Biosciences Inc., Celon Pharma , EyePoint Pharmaceuticals , Lupin Ltd, Novartis AG, and Pfizer Inc amongst others.
Request a Sample with TOC in a PDF format :https://www.marketresearchhub.com/enquiry.php?type=S&repid=1837699
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org